Presentations will include:
‘Homocysteine determination today – is it still relevant?’
‘Surprises from the study of patients with inherited disorders of cobalamin metabolism’
‘Combined indicator of B12 deficiency (cB12). Optimized sequential application of individual biomarkers and their combinations’
‘B vitamin status in non-pregnant, pregnant and lactating mothers and their infants’
‘Utility of new-born screening markers to diagnose new-borns at risk of vitamin B-12 deficiency second to maternal vitamin B-12 deficiency’
‘New perspectives on vitamin B-12 deficiency in low income populations: assessment and prevalence’.
‘Behavioural alterations associated with vitamin B12 deficiency in the TCblR/CD320 KO mouse’.
There’s even a presentation on the old classic debate about whether Cyanocobalamin or Hydroxocobalamin is best to treat Pernicious Anaemia – ‘Cyano-B12 versus hydroxo-B12: New insights on transport and accumulation’.
It’s heartening to know that so much research is taking place into the problems with the diagnosis and treatment of Pernicious Anaemia in particular and B12 Deficiency in general and we are grateful for the opportunity to be given the opportunity to give the patients’ perspective on these problems and to make the researchers not only aware of how late diagnosis and insufficient treatment is impacting on the lives of patients but also to make them aware of how we, as a society, can help them in their research programmes.